Kendra Avery
Director Xencor
Dr. Kendra Avery is Director of Protein Sciences & Technology at Xencor, where she leads early‑stage biologics discovery and therapeutic protein characterization. Her career spans roles at City of Hope and Texas A&M University, and she holds a PhD in Chemistry from Penn State University. Dr. Avery’s work includes contributions to bispecific antibody platforms and NK‑cell engager engineering.
Seminars
Thursday 25th June 2026
XmAb819: Avidity-Driven Selectivity in T-Cell Engagers Using Xencor’s 2+1 Platform
2:00 pm
- Discussing different T-Cell Engager configurations such as 1+1 and 2+1 as strategies for selectivity
- Examining how dual-antigen engagement enables simultaneously binding that increases functional avidity and exploring factors that impact avidity
- Presentation of pre-clinical and clinical data in RCC
Thursday 25th June 2026
Panel Discussion: Utilizing Discovery Platforms to Hunt for the Perfect Target & Advance T-Cell Engager Efficacy in Solid & Liquid Tumors
4:30 pm
- Discussing the methodologies currently used to identify antigens in multiple myeloma and B-cell lymphoma
- Debating whether therapeutic failure in hematologic cancers stems from T-cell exhaustion or from a lack of high-density, specific antigens to target
- Identifying shared antigens vs personalized neoantigens in solid tumor populations
